Full Press Release Details
Propanc Demonstrates Significant
Anti-Tumor Efficacy in Pancreatic and Ovarian Cancer Preclinical Models; Files Patent Specifying New Therapeutic Target Dose Range
MELBOURNE, AUSTRALIA, November 17th, 2015 -
Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company
focusing on development of new and proprietary treatments for cancer patients suffering from pancreatic and colorectal cancers,
today announced the Company has achieved significant tumor growth inhibition in pancreatic and ovarian cancers for PRP in recent
preclinical animal efficacy studies. The results from these studies were also used to file a new patent specifying a new target
efficacious dose range for future human studies.
"We are thrilled with the results and believe it now paves
the way for scientific advice meetings with regulatory agencies to determine the development pathway for human studies,"
said James Nathanielsz, Propanc's Chief Executive Officer, "As a result of achieving this significant milestone, we
are convinced PRP, which is a combination of two proenzymes, trypsinogen and chymotrypsinogen, could become a breakthrough treatment
in the fight against aggressive tumors like pancreatic and ovarian cancers. In fact, most common solid tumors."
In the pancreatic cancer study, Pan-02 mouse pancreatic tumor
cells were orthotopically inoculated (i.e. grafted into its normal place in the body) into immune competent (C57BL/6) mice. Treatment
with PRP injected once daily commenced nine days post inoculation, identified as Day 0. At Day 26, significant (p 0.05) reduction
in mean tumor weight was observed, 86% inhibition at the efficacious dose compared to the vehicle control.
In the ovarian cancer study, A2780 human ovarian cancer cells
were orthotopically inoculated in female, immune compromised (athymic Nude-Foxn1nu) mice. Treatment with PRP
injected once daily commenced seven days post inoculation, identified as Day 0. At Day 21, significant (p 0.05) reduction in
mean tumor weight was observed, 54% at the highest efficacious dose identified, and 48% at the lowest efficacious dose. Furthermore,
several mice in both treatment groups appear to have no tumor present upon final examination. This is despite identifying tumors
in all mice in the experimental control groups.
Further, all mice in the treatment groups exhibited no serious
adverse clinical signs in both studies.
Photographs of excised tumors taken from mice on the final day
of each study to assess anti-tumor efficacy of PRP are shown below.
"The results from these preclinical studies are conclusive
that PRP is effective in these tumor models," said Dr. Julian Kenyon, Propanc's Chief Scientific Officer. "What
is even more interesting, it appears that tumor models with immune functioning mice show markedly increased inhibitory effects,
which could possibly be attributed to the immunobiological effects of PRP, basically enhancing the immune response to assist with
tumor regression. As a result of this fine work undertaken with our preclinical research partners, we have identified an efficacious
dose range which we can now use to target in human studies."
Based on the results from the data, the Company has filed a
new patent application specifying novel proenzyme compositions at different dose ranges, which could be used to treat cancer. This
is in addition to its lead patent, which has commenced entering the national phase level in individual countries and regions, globally,
and is granted in Australia, South Africa and New Zealand.
Professor Klaus Kutz, Propanc's Chief
Medical Officer, said, "Now that we have proven scientific evidence in animals, which supports my evaluation of a number
of patients who significantly exceeded their life expectancy after being treated with proenzymes for compassionate use by Dr. Kenyon,
we are ready to prepare the next phase of our program for formal preclinical and clinical development of PRP. Given the correlation
between cellular, animal and human data, it is likely we will pursue pancreatic cancer as our primary target indication. Cancer
types like pancreatic and ovarian cancers could potentially qualify for orphan drug designation given the size of these patient
populations, which we are keen to explore."
Propanc is currently focused on developing new cancer treatments
for patients suffering from pancreatic and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert
a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve
or employ proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited
remaining therapeutic options for the treatment of solid tumors such as colorectal or pancreatic tumors. In future, we intend
to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure
for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Pan-02 Mouse Pancreatic Cancer Orthotopic Study in C57BL/6
Control vehicle, Day 26:
Post PRP treatment, Day 26
A2780 Human Ovarian Cancer Orthotopic Study in Female Athymic
Control vehicle, Day 21
PRP treated, highest efficacious dose
PRP treated, lowest efficacious dose
Forward-looking Statements:
Certain of the matters discussed in this announcement involve
risks and uncertainties including, without limitation, those regarding the Company's ability to establish and maintain the proprietary
nature of its technology through the patent process, its ability to license from others patents and patent applications, if necessary,
to develop certain products, its ability to implement its long range business plan for various applications of its technology,
and its ability to enter into agreements with any necessary marketing and/or distribution partners for purposes of commercialization.
This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position.
See Propanc's most recent Quarterly Report on Form 10-Q and related 8K filings.
Regal Consulting LLC